Literature DB >> 10567329

Opiate drugs and delta-receptor-mediated myocardial protection.

P E Benedict1, M B Benedict, T P Su, S F Bolling.   

Abstract

BACKGROUND: Hypothermic myocardial arrest is necessary to complete most cardiac surgery, which limits the success of such operations. Similarly, cold, inhospitable environments limit the survival of warm-blooded animals. Animals have successfully adapted to this challenge through hibernation. Hibernation is an energy-conserving state, now known to be governed by cyclical variation in endogenous opiate compounds. It may also be induced in nonhibernators via hibernating animal serum factors or delta-opiate peptides. Furthermore, hibernation-induction triggers extend organ preservation in many models. This study examined whether opiate drugs with an affinity for the delta-opiate receptor confer similar protection. METHODS AND
RESULTS: Isolated hearts harvested from New Zealand White rabbits were treated with either cardioplegia alone or delta-opiate drugs (fentanyl, morphine, buprenorphine, pentazocine) followed by 2 hours of 34 degrees C ischemia. Hearts were then reperfused, and functional and metabolic indices of treated groups were compared with untreated controls. Isovolumic developed pressure, coronary flow, and oxygen consumption were compared as a percent of preischemia versus 45 minutes after reflow. Developed pressure and oxygen consumption were better preserved in the morphine, buprenorphine, and pentazocine groups when compared with cardioplegia alone.
CONCLUSIONS: Drugs with delta-opiate activity confer myocardial protection, which is additive to cardioplegia. Use of delta-opiate drugs in this context may have important clinical implications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567329     DOI: 10.1161/01.cir.100.suppl_2.ii-357

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

1.  The effect of the enkephalin DADLE on transcription does not depend on opioid receptors.

Authors:  Beatrice Baldelli; Lorella Vecchio; Maria Grazia Bottone; Giovanni Muzzonigro; Marco Biggiogera; Manuela Malatesta
Journal:  Histochem Cell Biol       Date:  2006-01-14       Impact factor: 4.304

2.  DADLE induces a reversible hibernation-like state in HeLa cells.

Authors:  Lorella Vecchio; Cristiana Soldani; Maria Grazia Bottone; Manuela Malatesta; Terence E Martin; Lawrence I Rothblum; Carlo Pellicciari; Marco Biggiogera
Journal:  Histochem Cell Biol       Date:  2005-10-18       Impact factor: 4.304

3.  Effect of opium use on short-term outcome in patients undergoing coronary artery bypass surgery.

Authors:  Nasser Safaii; Babak Kazemi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-02-13

4.  A murine closed-chest model of myocardial ischemia and reperfusion.

Authors:  Se-Chan Kim; Olaf Boehm; Rainer Meyer; Andreas Hoeft; Pascal Knüfermann; Georg Baumgarten
Journal:  J Vis Exp       Date:  2012-07-17       Impact factor: 1.355

Review 5.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

Review 6.  A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain.

Authors:  Jeffrey Gudin; Jeffrey Fudin
Journal:  Pain Ther       Date:  2020-01-28

Review 7.  Knocking Out Sigma-1 Receptors Reveals Diverse Health Problems.

Authors:  Simon Couly; Nino Goguadze; Yuko Yasui; Yuriko Kimura; Shao-Ming Wang; Nino Sharikadze; Hsiang-En Wu; Tsung-Ping Su
Journal:  Cell Mol Neurobiol       Date:  2020-10-23       Impact factor: 5.046

8.  Relation of opium addiction with the severity and extension of myocardial infarction and its related mortality.

Authors:  Farnaz Dehghani; Mohammad Masoomi; Ali Akbar Haghdoost
Journal:  Addict Health       Date:  2013 Winter-Spring
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.